NCT05083312View on ClinicalTrials.gov

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

September 5, 2022

Study Completion Date

September 5, 2022

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

APT-1011

APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.

DRUG

Placebo oral tablet

Placebo orally disintegrating tablet

Trial Locations (3)

3052

Royal Children's Hospital, Melbourne

46202

IU School of Medicine Department of Pediatrics, Indianapolis

02111

Boston Specialists, Boston

Sponsors
All Listed Sponsors
lead

Ellodi Pharmaceuticals, LP

INDUSTRY